Dr. Drilon on the Utility of Brigatinib in ALK+ NSCLC

Supplements And Featured PublicationsTargeted Advances in ALK+ NSCLC
Volume 1
Issue 1

In Partnership With:

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

Alexander Drilon, MD, research director, Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses the utility of brigatinib (Alunbrig) in ALK-positive non—small cell lung cancer (NSCLC).

Brigatinib is a next-generation TKI designed to have activity against wild-type ALK fusions and other treatment-related resistance mechanisms, says Drilon. In April 2017, the FDA granted an accelerated approval to brigatinib for the treatment of patients with ALK-positive metastatic NSCLC who are resistant to or intolerant of crizotinib (Xalkori).

Updated results from the randomized phase III ALTA-1L trial show that brigatinib leads to superior progression-free survival versus the prior standard of care crizotinib in patients with advanced ALK-positive NSCLC who had not received a prior ALK inhibitor. Findings from the trial showed that brigatinib led to a 51% reduction in the risk of disease progression or death versus crizotinib by blinded independent review committee (BIRC) assessment (HR, 0.49; 95% CI, 0.35-0.68; log-rank P <.0001).

The BIRC-assessed median progression-free survival was 24.0 months (95% CI, 18.5—NE) with brigatinib versus 11.0 months (95% CI, 9.2-12.9) with crizotinib. The BIRC-assessed objective response rate was 74% and 62% with brigatinib and crizotinib, respectively.

Additionally, brigatinib demonstrated meaningful central nervous system activity and led to a 69% reduction in the risk of intracranial disease progression or death in patients who had brain metastases at baseline (HR, 0.31; 95% CI, 0.17-0.56).

Related Videos
Catherine Ann Shu, MD
Christine Bestvina, MD
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
A panel of 6 experts on breast, lung, and gastrointestinal cancers
Mark A. Socinski, MD, an expert on lung cancer, presenting slides